Please use this identifier to cite or link to this item: http://localhost:80/xmlui/handle/123456789/15999
Title: Dissolution rate enhancement of new co-crystals of ezetimibe with maleic acid and isonicotinamide
Authors: Wen, Li
Man, Zhao
Yu-zhen, Yu
Yan-jie, Hu
Xiao-hui, Zhang
Kai, Sun
Ling, Fu
Li Na, Ding
Keywords: Ezetimibe
maleic acid
isonicotinamide co-crystal
solubility
dissolution
Issue Date: 7-Jul-2019
Publisher: Karachi: Faculty of Pharmacy & Pharmaceutical Sciences University of Karachi
Citation: Wen, L., Man, Z., Yu-Zhen, Y., Yan-Jie, H., Xiao-Hui, Z., Kai, S., ... & Na, D. L. (2019). Dissolution rate enhancement of new co-crystals of ezetimibe with maleic acid and isonicotinamide. Pakistan Journal of Pharmaceutical Sciences, 32(4).
Abstract: Ezetimibe (EZT) is a selective cholesterol absorption inhibitor with poor aqueous solubility (0.012mg/ml 23 oC) and low oral bioavailability (about 35-65% for a once 10mg dose). The present study illustrates the preparation and characterization of two new co-crystals of ezetimibe using maleic acid and isonicotinamide as the coformers by solid grinding method. The co-crystal structures were characterized by X-ray powder diffraction (PXRD), differential scanning calorimetry (DSC), infrared spectroscopy (IR) techniques. Crystallinity and surface morphological characteristics of these prepared co-crystals were observed by scanning electron microscope (SEM). Dissolution rate tests demonstrated that both of the new co-crystals showed significant improvement in sodium lauryl sulfate -sodium acetate buffer solution (PH=4.5) at 15min and 20min. This study enriched the types of EZT co-crystals and identified that pharmaceutical co-crystal engineering technique play an important role in the dissolution rate enhancement of ezetimibe.
URI: http://142.54.178.187:9060/xmlui/handle/123456789/15999
ISSN: 1011-601X
Appears in Collections:Issue 4

Files in This Item:
File Description SizeFormat 
Paper-7.htm130 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.